Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial

Table 5 Adverse events with an incidence of more than 5% in any treatment groups ^a

AE	Placebo group ( n = 46)		5 mg group ( n = 47)		10 mg group ( n = 49)
AE	AEs	Treatment-related AEs ^b	AEs	Treatment-related AEs ^b	AEs	Treatment-related AEs ^b
Total incidence	31 (67.4)	11 (23.9)	30 (63.8)	12 (25.5)	34 (69.4)	14 (28.6)
Nausea	1 (2.2)	1 (2.2)	3 (6.4)	2 (4.3)	1 (2.0)	1 (2.0)
Pyrexia	0	0	0	0	3 (6.1)	0
Nasopharyngitis	7 (15.2)	0	4 (8.5)	0	2 (4.1)	0
Contusion	4 (8.7)	0	0	0	1 (2.0)	0
Decreased appetite	1 (2.2)	1 (2.2)	3 (6.4)	1 (2.1)	2 (4.1)	2 (4.1)
Parkinsonism	2 (4.3)	2 (4.3)	2 (4.3)	2 (4.3)	4 (8.2)	4 (8.2)
Pollakiuria	0	0	3 (6.4)	3 (6.4)	0	0

^aAE, Adverse event. Incidence shown as number and percentage. ^bAEs for which a causal relationship with the study drug was considered possible or probable.

ISSN: 1758-9193